JP2009542622A5 - - Google Patents

Download PDF

Info

Publication number
JP2009542622A5
JP2009542622A5 JP2009517603A JP2009517603A JP2009542622A5 JP 2009542622 A5 JP2009542622 A5 JP 2009542622A5 JP 2009517603 A JP2009517603 A JP 2009517603A JP 2009517603 A JP2009517603 A JP 2009517603A JP 2009542622 A5 JP2009542622 A5 JP 2009542622A5
Authority
JP
Japan
Prior art keywords
peptide
agent
seq
copolymer
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009517603A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009542622A (ja
JP5412280B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2007/000798 external-priority patent/WO2008001380A2/en
Publication of JP2009542622A publication Critical patent/JP2009542622A/ja
Publication of JP2009542622A5 publication Critical patent/JP2009542622A5/ja
Application granted granted Critical
Publication of JP5412280B2 publication Critical patent/JP5412280B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009517603A 2006-06-28 2007-06-28 加齢性黄斑変性症の治療法 Expired - Fee Related JP5412280B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80604106P 2006-06-28 2006-06-28
US60/806,041 2006-06-28
PCT/IL2007/000798 WO2008001380A2 (en) 2006-06-28 2007-06-28 Method of treatment of age-related macular degeneration

Publications (3)

Publication Number Publication Date
JP2009542622A JP2009542622A (ja) 2009-12-03
JP2009542622A5 true JP2009542622A5 (enExample) 2010-09-24
JP5412280B2 JP5412280B2 (ja) 2014-02-12

Family

ID=38846104

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009517603A Expired - Fee Related JP5412280B2 (ja) 2006-06-28 2007-06-28 加齢性黄斑変性症の治療法

Country Status (7)

Country Link
US (1) US9089509B2 (enExample)
EP (1) EP2046366B1 (enExample)
JP (1) JP5412280B2 (enExample)
AU (1) AU2007264682B2 (enExample)
CA (1) CA2656463C (enExample)
ES (1) ES2605154T3 (enExample)
WO (1) WO2008001380A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008075365A1 (en) * 2006-12-20 2008-06-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions and methods for treatment of age related degeneration of the retina
AU2010216374A1 (en) * 2009-02-20 2011-08-18 The Scripps Research Institute Isolated monocyte populations and related therapeutic applications
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
ES2601892T3 (es) 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
US20130217986A1 (en) * 2012-02-21 2013-08-22 Ucl Business Plc Method and system for predicting an amyloidosis status
US20180140626A1 (en) * 2015-05-14 2018-05-24 Joslin Diabetes Center, Inc. Retinol-binding protein 3 (rbp3) as a protective factor in non-diabetic retinal degeneration
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en) 2016-08-31 2024-09-05 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
AU2018206358B2 (en) * 2017-01-04 2021-05-27 Worg Pharmaceuticals (Zhejiang) Co., Ltd. S-Arrestin peptides and therapeutic uses thereof
IL316573A (en) 2017-03-26 2024-12-01 Mapi Pharma Ltd Storage systems containing glatiramer acetate for the treatment of multiple sclerosis
WO2021188761A1 (en) * 2020-03-18 2021-09-23 University Of Florida Research Foundation, Incorporated Modified arrestin-1 to enhance photoreceptor survival in retinal disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
IL113812A (en) 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
JP2003521448A (ja) 1998-07-23 2003-07-15 ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 合成ペプチドおよび自己免疫疾患治療のための使用方法
EP1098902A4 (en) 1998-07-23 2002-07-24 Yeda Res & Dev TREATMENT OF AUTOIMMUNE DISEASES WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES
US20030149997A1 (en) * 1999-02-19 2003-08-07 Hageman Gregory S. Diagnostics and therapeutics for arterial wall disruptive disorders
US6420378B1 (en) * 1999-10-15 2002-07-16 Supergen, Inc. Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
HK1054507B (zh) * 2000-01-20 2008-10-31 耶达研究及发展有限公司 共聚物1和相关肽和多肽及其处理过的t细胞在神经保护性治疗中的用途
US7399740B2 (en) * 2001-06-28 2008-07-15 Yeda Research And Development Co. Ltd. Poly-Glu,Tyr for neuroprotective therapy
US6524012B1 (en) * 2001-09-06 2003-02-25 Gkn Automotive, Inc. Securing members together by spring rings
WO2003064706A1 (en) * 2002-01-25 2003-08-07 Biomedical Design, Inc. Calcification-resistant fixation
US20050220803A1 (en) * 2002-03-26 2005-10-06 Yeda Research And Development Co. Ltd. Use of an organ-specific self-pathogen for treatment of a non-autoimmune disease of said organ
EP1578199A2 (en) * 2002-06-14 2005-09-28 Yeda Research And Development Company, Ltd. Antigen-presenting cells for neuroprotection and nerve regeneration
US7860975B2 (en) * 2002-07-31 2010-12-28 Oracle America, Inc. System and method for secure sticky routing of requests within a server farm
US7354574B2 (en) * 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
WO2004060265A2 (en) * 2003-01-07 2004-07-22 Yeda Research And Development Co. Ltd. Eye-drop vaccine containing copolymer 1 for therapeutic immunization

Similar Documents

Publication Publication Date Title
ES2598005T3 (es) Uso de IL-15 para aumentar la salida del timo y para tratar la linfopenia
KR101554056B1 (ko) 자가면역 질환의 치료 및/또는 예방 및 조절 ｔ세포의 형성을 위한 수단
DK2864360T3 (en) TARGETED THERAPY
ES2924027T3 (es) Péptidos inmunogénicos para su uso en la prevención y/o tratamiento de enfermedades infecciosas, enfermedades autoinmunitarias, respuestas inmunitarias a alofactores, enfermedades alérgicas, tumores, rechazo de injerto y respuestas inmunitarias contra vectores virales usados para terapia génica o vacunación génica
JP2023506757A5 (enExample)
EP2479277A3 (en) Compositions and methods of use for MGD-CSF in disease treatment
EP2848627A3 (en) Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
TW200944226A (en) Biologically active peptides
CA2355400A1 (en) Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd
US9790264B2 (en) Compounds and methods for modulating pharmacokinetics
JP2019530441A5 (enExample)
CN104623639A (zh) 白介素22二聚体在制备治疗胰腺炎药物中的应用
EP2989121B1 (en) Methods of preparation and composition of peptide constructs useful for treatment of rheumatoid arthritis
CN117751136A (zh) 用于治疗自身免疫的工程化hla等位基因
JP2010535504A5 (enExample)
AU2019219072A1 (en) Modified immunomodulatory peptide
RU2011150283A (ru) Пептиды ттк и вакцины, их содержащие
RU2011140168A (ru) Пептиды vangl1 и содержащие их вакцины
Kozhich et al. Immunogenicity and immunopathogenicity of an autoimmune epitope are potentiated by increasing MHC binding through residue substitution
Briand et al. Emerging peptide therapeutics for inflammatory autoimmune diseases
US20160158330A1 (en) Methods of preparation and composition of peptide constructs useful for treatment of rheumatoid arthritis
WO2025119999A1 (en) Extracellular vesicle based vaccine platform